Moderna shares dropped as much as 25% following the leak of partial data on its closely watched cancer vaccine developed with Merck.The stock fell even though the full data, released later Thursday following the leak, appeared positive relative to Wall Street expectations. (CNBC)
Telehealth companies are prescribing GLP-1 drugs for addiction without FDA approval for that use.Some online platforms are already marketing the medications for alcohol and other substance use disorders, even as clinical trials continue and experts warn that patients may be left to weigh the risks and benefits themselves. (STAT News)
The Centers for Disease Control and Prevention ignored a request from states to validate a new measles test.Health officials in California and Washington, facing outbreaks of measles this past spring, asked the Centers for Disease Control and Prevention in May to validate a test that can diagnose 500 cases in eight hours. They did not hear back for two months. (The New York Times)
Rumors are swirling that the Treasury Department is going to propose a rule that restricts U.S. investment in the ascendant Chinese biotech sector. Targeting the so-called “#Chinathreat,” the act curbs business with Chinese firms like WuXi AppTec and BGI Genomics under national security regulations. (Endpoints News)
Roche posted a healthy 7% growth for its pharmaceutical division in the first nine months of 2026, though the drugmaker discontinued several clinical programmes amid asset prioritization.Sales for Roche’s medicines reached $44 billion for the period, denoting just under 80% of the company’s total sales. (The Wall Street Journal)
Click here to see yesterday’s Five things for pharma marketers to know.
